Postmenopausal Osteoporosis: From Molecular Pathways to Therapeutic Targets-A Mechanism-to-Practice Framework Integrating Pharmacotherapy, Fall Prevention, and Adherence into Patient-Centered Care.
Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study.
AuteursBhave M, Jhaveri KL, Kaufman PA, Aftimos P, Lombard J, Giridhar KV, Im SA, Ma CX, Lee KT, Kim SB, Sohn J, Li Y, Yuen E, Estrem ST, Nguyen B, Makena MR, Ismail-Khan R, Beeram M
HER2/CEP17 ratio is associated with pCR after HER2-directed neoadjuvant treatment in the phase III NeoALTTO trial.
AuteursSinger CF, Koenig F, Kacerovsky-Strobl S, Danzinger S, Brunner C, Suppan C, Deutschmann C, Balic M, Greil R, Egle D, de Azambuja E, Di Cosimo S, Choudhury A, Gnant M
AuteursPansieri J, Figiel S, Menassa D, Ricigliano VAG, Seferoglu M, Borrelli S, Szejko N, Samadzadeh S, Boldrini V, Zarco L, Correa-Díaz EP, Pozzilli V, Marenna S, Carnero Contentti E, Koc ER, Dalla Costa G, Casallas-Vanegas A, Bakirtzis C, Gluscevic S, Tunç A, Gomez Figueroa E